News Releases

April 1, 2021
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
CAMBRIDGE, Mass. , April 1, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
March 25, 2021
Synlogic Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-- SYNB8802 advances to Phase 1B Proof of Concept After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria Study -- -- Synlogic ended 2020 with $100.4 million in cash, cash equivalents, and short-term investments, extending projected runway into 2023 -- -- Management to host conference call...
March 24, 2021
Synlogic Announces SYNB8802 Will Advance to Phase 1B Proof of Concept Study After Proof of Mechanism Demonstrated in Dietary Hyperoxaluria
- 28.6% Urinary Oxalate lowering demonstrated in Dietary Hyperoxaluria in healthy volunteers - - Part B in Enteric Hyperoxaluria patients initiated - CAMBRIDGE, Mass. , March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of...
March 16, 2021
Synlogic Announces Fourth Quarter and Full Year 2020 Conference Call & Webcast
CAMBRIDGE, Mass. , March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its fourth quarter and full year 2020 financial results before the market opens...
March 8, 2021
Synlogic Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer and Strengthening of Leadership Team
CAMBRIDGE, Mass. , March 8, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Dr. Caroline Kurtz to Chief Development Officer. As Chief Development Officer, Dr....
February 15, 2021
Synlogic to Present at Upcoming Virtual Banking and Industry Conferences
CAMBRIDGE, Mass. , Feb. 15, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife Brennan , M.B. Ch.B., Synlogic's President and Chief Executive Officer, and other members of...
February 10, 2021
Synlogic Appoints Lisa Kelly-Croswell to its Board of Directors
CAMBRIDGE, Mass. , Feb. 10, 2021 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Lisa Kelly-Croswell to its board of directors....
February 2, 2021
Joint Team from MIT and Synlogic Named a Biotechnology Grand Challenge Winner by Air Force Research Laboratory
- Synlogic to provide bioprocess and manufacturing in joint effort to engineer novel investigational medicines to address battle fatigue - CAMBRIDGE, Mass. , Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the...
January 11, 2021
Synlogic Outlines Upcoming Clinical Milestones
- Clinical proof of concept data in 2021 anticipated across multiple programs - CAMBRIDGE, Mass. , Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant clinical...
December 14, 2020
Synlogic Announces Advancement of SYNB1891 to Combination Arm Dosing with PD-L1 Checkpoint Inhibitor in the on-going Phase 1 Study for the Treatment of Solid Tumors and Lymphoma
- SYNB1891 demonstrates STING activation and target engagement in the tumor microenvironment in monotherapy cohorts - CAMBRIDGE, Mass. , Dec. 14, 2020 /PRNewswire/ --  Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine,...
December 9, 2020
Synlogic Appoints Michael Heffernan to its Board of Directors
CAMBRIDGE, Mass. , Dec. 9, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appointment of Michael Heffernan to its board of directors....
December 7, 2020
Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering
CAMBRIDGE, Mass. , Dec. 7, 2020 /PRNewswire/ --  Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it will present additional translational and in silico data on SYNB8802, a Synthetic Biotic medicine...
Displaying 25 - 36 of 156